KalVista Pharmaceuticals, Inc. (KALV): debt financing — KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY

KalVista Pharmaceuticals, Inc.

Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.
Net proceeds ~$139M after discounts and expenses; used for working capital and EKTERLY commercialization.
Initial conversion rate 59.4919 shares/$1,000 (conversion price ~$16.81), 30% premium over $12.93 close.
Notes are senior, unsecured, callable after Oct 5, 2028 if stock price meets 130% conversion price threshold.

item 1.01 item 8.01 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

KalVista Pharmaceuticals, Inc. incurred convertible notes of $143.75 million in aggregate principal amount with Initial Purchasers at 3.250% maturing due 2031.

Instrument: convertible notes
Principal: $143.75 million in aggregate principal amount
Counterparty: Initial Purchasers
Rate: 3.250%
Maturity: due 2031
Event: incurrence

Exact text from the filing

On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031

View on SEC.gov

304 debt financings filed in the last 30 days. Browse all debt financings →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-223262

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.